Effectiveness of Pegylated Interferon and Ribavirin for Chronic Hepatitis C
Author Information
Author(s): Nanna Hansen, Niels Obel, Peer B. Christensen, Mette Kjær, Alex L. Laursen, Henrik B. Krarup, Axel Møller, Poul Schlichting, Jens Bukh, Nina Weis
Primary Institution: Copenhagen University Hospital
Hypothesis
What is the effectiveness of peginterferon and ribavirin treatment in unselected patients with chronic hepatitis C in routine clinical practice?
Conclusion
The treatment effectiveness of peginterferon and ribavirin for chronic hepatitis C in routine clinical practice is comparable to that observed in controlled clinical trials.
Supporting Evidence
- Patients with genotype 2/3 had a higher SVR rate compared to those with genotype 1.
- Age ≤ 45 years at treatment initiation was associated with a higher chance of SVR.
- Completion of unmodified treatment regimens predicted better treatment outcomes.
Takeaway
This study shows that pegylated interferon and ribavirin can effectively treat hepatitis C, especially in younger patients and those with certain virus types.
Methodology
The study analyzed the sustained virological response (SVR) in a nationwide cohort of 432 patients using logistic regression to assess predictors of SVR.
Potential Biases
Selection bias may exist due to the observational nature of the study.
Limitations
The study is retrospective and lacks information on some confounders like weight and prior psychiatric conditions.
Participant Demographics
The cohort included 432 patients, with a median age of 46 years, and a mix of European and non-European nationalities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website